Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) was established on June 26, 2008, headquartered in Cambridge, Massachusetts, USA, with 24 full-time employees (9/30/2018). It is a clinical stage biopharmaceutical company focusing on development and development And commercialize its proprietary technology innovation therapy platform for metabolic problems.
Catabasis Pharmaceuticals (CATB):
Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focusing on the discovery, development and commercialization of therapeutic drugs based on the US Safe Metabolism and Reasonable Targeting (SMART) drug discovery platform.
Catabasis Pharmaceutical’s innovative therapeutic linker (Linker) technology platform is based on the concept of “simultaneously regulating multiple biological targets in one or more related diseases to treat diseases”. The dual-functional candidate product designed by Catabasis is two molecules ( Biologically active substances) each have a known pharmacological activity and are combined through its proprietary smart linker.
Catabasis Pharmaceuticals’ main product candidate is Edasalonexent, an oral small molecule that has completed phase II clinical trials for the treatment of duchenne muscular dystrophy (DMD) and phase I clinical trials for the treatment of other rare diseases.
Catabasis Pharmaceuticals is also involved in the development of SMART-linked conjugates in the pre-clinical development stage, including CAT-5571 for cystic fibrosis (CF) and dysfunction of CF transmembrane conduction regulators, as well as for removing pathogens such as verdigris Monas and B. cenocepacia; and CAT-4001 are used to treat severe and rare neurodegenerative diseases consisting of Friedreich’s ataxia and amyotrophic lateral sclerosis.
In addition, the company also provides CAT-2000 compounds, which are SMART-linked conjugates of niacin and EPA for the treatment of non-alcoholic steatohepatitis.
Catabasis Pharmaceuticals and Sarepta Therapeutics signed a pre-clinical joint research cooperation agreement to explore the combined drug treatment of DMD; and cooperated with the University of Texas Southwest to study the potential benefits of edasalonexent treatment.
Catabasis Pharmaceuticals (CATB) investment:
Catabasis submitted its IPO documents to the SEC on May 13, 2015. It was listed on the Nasdaq on June 25 of the same year. The issue price was US$12. It issued 5 million shares and raised US$60 million. The stock code: CATB.